» Articles » PMID: 27092244

Cell Biology and Genetics of Minimal Change Disease

Overview
Journal F1000Res
Date 2016 Apr 20
PMID 27092244
Citations 18
Authors
Affiliations
Soon will be listed here.
Abstract

Minimal change disease (MCD) is an important cause of nephrotic syndrome and is characterized by massive proteinuria and hypoalbuminemia, resulting in edema and hypercholesterolemia. The podocyte plays a key role in filtration and its disruption results in a dramatic loss of function leading to proteinuria. Immunologic disturbance has been suggested in the pathogenesis of MCD. Because of its clinical features, such as recurrent relapse/remission course, steroid response in most patients, and rare familial cases, a genetic defect has been thought to be less likely in MCD. Recent progress in whole-exome sequencing reveals pathogenic mutations in familial cases in steroid-sensitive nephrotic syndrome (SSNS) and sheds light on possible mechanisms and key molecules in podocytes in MCD. On the other hand, in the majority of cases, the existence of circulating permeability factors has been implicated along with T lymphocyte dysfunction. Observations of benefit with rituximab added B cell involvement to the disease. Animal models are unsatisfactory, and the humanized mouse may be a good model that well reflects MCD pathophysiology to investigate suggested "T cell dysfunction" directly related to podocytes in vivo. Several candidate circulating factors and their effects on podocytes have been proposed but are still not sufficient to explain whole mechanisms and clinical features in MCD. Another circulating factor disease is focal segmental glomerulosclerosis (FSGS), and it is not clear if this is a distinct entity, or on the same spectrum, implicating the same circulating factor(s). These patients are mostly steroid resistant and often have a rapid relapse after transplantation. In clinical practice, predicting relapse or disease activity and response to steroids is important and is an area where novel biomarkers can be developed based on our growing knowledge of podocyte signaling pathways. In this review, we discuss recent findings in genetics and podocyte biology in MCD.

Citing Articles

RESOLVE: Recurrence Posttransplant Observational Study in Focal Segmental Glomerulosclerosis and Minimal Change Disease.

Salmon E, Rahimi A, Desmond H, Putnam N, Martinelli E, Hendren E Glomerular Dis. 2025; 5(1):60-67.

PMID: 39991191 PMC: 11842035. DOI: 10.1159/000542839.


Detailed Pathophysiology of Minimal Change Disease: Insights into Podocyte Dysfunction, Immune Dysregulation, and Genetic Susceptibility.

Roman M, Nowicki M Int J Mol Sci. 2024; 25(22).

PMID: 39596249 PMC: 11595011. DOI: 10.3390/ijms252212174.


Association of ABCB1(Rs10276036, C/T) Gene, IL-18, and TNFα as Risk Factors for Nephrotic Syndrome Incidence.

Aly Hassan E, Mohamed Elsaid A, Mahmoud El-Refaey A, Abou Elzahab M, Mahfouz Youssef M, Elmougy R Rep Biochem Mol Biol. 2024; 13(1):67-78.

PMID: 39582831 PMC: 11580123. DOI: 10.61186/rbmb.13.1.67.


Anti-Tumor Necrosis Factor Treatment for Glomerulopathy: Case Report and Review of Literature.

Jones O, Malone L, Brunson C Fed Pract. 2024; 41(8):250-255.

PMID: 39410922 PMC: 11473030. DOI: 10.12788/fp.0506.


Review of the Role of Rituximab in the Management of Adult Minimal Change Disease and Immune-Mediated Focal and Segmental Glomerulosclerosis.

Aslam A, Koirala A Glomerular Dis. 2023; 3(1):211-219.

PMID: 37901702 PMC: 10601923. DOI: 10.1159/000533695.


References
1.
Trautmann A, Bodria M, Ozaltin F, Gheisari A, Melk A, Azocar M . Spectrum of steroid-resistant and congenital nephrotic syndrome in children: the PodoNet registry cohort. Clin J Am Soc Nephrol. 2015; 10(4):592-600. PMC: 4386250. DOI: 10.2215/CJN.06260614. View

2.
Bruchfeld A, Benedek S, Hilderman M, Medin C, Snaedal-Jonsdottir S, Korkeila M . Rituximab for minimal change disease in adults: long-term follow-up. Nephrol Dial Transplant. 2013; 29(4):851-6. DOI: 10.1093/ndt/gft312. View

3.
Saleem M . One hundred ways to kill a podocyte. Nephrol Dial Transplant. 2015; 30(8):1266-71. DOI: 10.1093/ndt/gfu363. View

4.
Alfano M, Cinque P, Giusti G, Proietti S, Nebuloni M, Danese S . Full-length soluble urokinase plasminogen activator receptor down-modulates nephrin expression in podocytes. Sci Rep. 2015; 5:13647. PMC: 4585377. DOI: 10.1038/srep13647. View

5.
. The primary nephrotic syndrome in children. Identification of patients with minimal change nephrotic syndrome from initial response to prednisone. A report of the International Study of Kidney Disease in Children. J Pediatr. 1981; 98(4):561-4. DOI: 10.1016/s0022-3476(81)80760-3. View